Health & Education · Milan and Olginate

Sardinia seeks faster access to pancreatic cancer drug daraxonrasib as Italy debates costs

A unanimous resolution in Sardinia's regional council asks for faster access to daraxonrasib, while Lombardy plans its own protocol and Italian price talks with AIFA remain pending.

AI text based on reports by Tgcom24, ANSA.it, Il Messaggero and other publishers. Published . How it is made

For membersThe first 30 seconds for everyone. Synthetic voice (AI).

In brief

Milan, Olginate · Italy
How it came to this
  1. May 2024Max Parisi is diagnosed with pancreatic cancer
  2. 16 SeptParisi starts daraxonrasib therapy in the United States
  3. November 2026Reported tumour shrinkage of 1.5 cm after less than two months of treatment

Where the approval stands

Daraxonrasib, a pill for metastatic pancreatic adenocarcinoma, has been authorised in the United States by the Food and Drug Administration. Sources disagree on its European stage. Fanpage reports that the European Commission authorised marketing on Monday, 16 November, for adults who have already had at least one systemic therapy. ANSA and Michele Reni instead describe an EMA committee recommendation, with the European marketing authorisation still pending. In Italy, AIFA must still assess the dossier and negotiate a price with the manufacturer Revolution Medicines before the drug can be reimbursed. Trial data show average survival of 12 months against 6.7 with standard chemotherapy.

Sardinia and Lombardy

On 19 November, the Sixth Commission of the Sardinian regional council, which handles health, approved a resolution on access unanimously. It commits the regional government to work with the Ministry of Health and AIFA on the legal and administrative conditions for making the drug available before the European procedure concludes. The text also asks for information on the protocol Lombardy has said it intends to define for some patients, and for a count of Sardinian patients who could be eligible. The aim is to avoid differences between regions while national rules are absent. The regional council building is to be lit purple on 19 November for World Pancreatic Cancer Day, which falls each year on the third Thursday of November.

Patients looking abroad

Patients with advanced disease are looking for the drug outside Italy. Max Parisi, a Radio Monte Carlo presenter, was diagnosed in May 2024 and was told in July that his treatment options were exhausted. His wife contacted American hospitals and found daraxonrasib, which was approved at the end of August for specific metastatic patients who had already undergone other treatments. He began therapy in the United States on 16 September.

Parisi wrote on social media that the drug works and that he continues the treatment.

“The drug works and I am continuing the treatment at full speed.”

Max Parisi

Reports say his tumour mass shrank by 1.5 cm after less than two months, and he will return to air on Monday, 23 November. His family launched a fundraiser for a course that costs roughly 40,000 dollars a month, according to Tgcom. Il Messaggero gives a figure of about 35,000 euros and Il Fatto Quotidiano about 40,000 euros.

Reported private monthly cost of daraxonrasib in ItalyEUR per month
Il Messaggero
35000 EUR per month
Il Fatto Quotidiano
40000 EUR per month

Data from the article text

In early November, a 36-year-old mother of twins aged three and a half, from the Lecco area, launched her own fundraiser for the therapy. Lombardy's welfare assessor Guido Bertolaso then said the region would buy the drug so she could access treatment. Il Messaggero reports that requests have since come from other families across Italy.

Expert views on benefit and care

Michele Reni, clinical coordinator of the Pancreas Center at San Raffaele in Milan, says the drug gives three to four more months of disease control compared with a non-optimal chemotherapy used in the trial, but long-term data are missing. He describes benefit as a continuum, ranging from none to prolonged, with toxicity varying between patients. Piero Rivizzigno, president of Codice Viola, argues that organised care can match some approved drugs.

“An improvement in how care is organised can bring benefits comparable to, if not greater than, those of some drugs approved under the protocols.”

Piero Rivizzigno

He points to Lombardy's Pancreas Units, where 90-day post-surgery mortality fell from 8.1% to 5.3% in 2025, which he says means 30 fewer deaths. The national Agenas outcomes plan is due late in December. Domenico Traversa, whose wife Paola Marella died of pancreatic cancer in 2024, warns that the drug is not indicated for all metastatic patients and that access should not depend on region or income.

Ask about this text

Sources and context

Pollar is free and carries no ads in the text. Its members keep it going.

Support Pollar